Table 1.
Baseline characteristics of hematopoietic stem cell transplant (HSCT) recipients with ≥1 post‐transplant human rhinovirus (HRV) infections
| Variable | N = 63 (%) patients |
|---|---|
| Female | 25 (40) |
| Median age at HSCT (range) | 55 (21–71) |
| Primary hematologic disorder | |
| Acute leukemia | 26 (41) |
| Lymphoma | 20 (32) |
| Multiple myeloma | 10 (16) |
| Chronic myelogenous leukemia | 3 (5) |
| Other | 4 (6) |
| Transplant type | |
| Allogeneic | 42 (67) |
| Matched‐related donor | 19/42 (45) |
| Matched‐unrelated donor | 14/42 (33) |
| Mismatched‐unrelated donor | 1/42 (2) |
| Cord blood | 8/42 (19) |
| Autologous | 20 (32) |
| Syngeneic | 1 (2) |
| Conditioning regimen | |
| Myeloablative | 42 (67) |
| Reduced‐intensity | 21 (33) |
| Graft‐versus‐host disease (GVHD)a , b | 21/42 (50) |
| Comorbidities | |
| Chronic obstructive pulmonary disease/Asthma | 6 (10) |
| Other post‐transplant lung diseasec | 7 (11) |
| Tobacco use currentd | 8 (13) |
| Tobacco use ever | 27 (43) |
| Diabetes | 10 (16) |
| History of pneumonia within previous 30 days | 0 |
| Visit type at first HRV infection | |
| Inpatient | 36 (57) |
| Admission for HSCT | 17 (27) |
| Admission for acute reason | 19 (30) |
| Outpatient | 27 (43) |
Includes patients with acute GVHD grade 2–4 and/or chronic GVHD.
An additional 10 subjects were diagnosed with GVHD during the 1‐year follow‐up period.
Bronchiolitis obliterans (N = 5), Idiopathic pulmonary fibrosis (N = 1), Interstitial pneumonitis (N = 1).
Defined as tobacco use within the previous 12 months.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.